Suppr超能文献

一氧化氮作为硫酸镁泻药作用的介质。

Nitric oxide as a mediator of the laxative action of magnesium sulphate.

作者信息

Izzo A A, Gaginella T S, Mascolo N, Capasso F

机构信息

Department of Experimental Pharmacology, University of Naples, Italy.

出版信息

Br J Pharmacol. 1994 Sep;113(1):228-32. doi: 10.1111/j.1476-5381.1994.tb16198.x.

Abstract
  1. Magnesium sulphate was studied for its effects on diarrhoea, fluid secretion, gastrointestinal transit and nitric oxide (NO) synthase activity in rats. 2. At a dose of 2 g kg-1 orally magnesium sulphate produced diarrhoea that was delayed in onset and intensity in a dose-related manner by the NO synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME). This was prevented by the NO precursor, L-arginine and the NO donating compound, isosorbide-5-mononitrate (IMN). 3. Nitric oxide synthase activity was stimulated in gut tissue from rats given magnesium sulphate and this was inhibited by L-NAME. Dexamethasone (1 mg kg-1, i.p.), an inhibitor of inducible NO synthase, had no effect on magnesium sulphate-induced diarrhoea. 4. Magnesium sulphate stimulated fluid and electrolyte accumulation in the intestinal lumen; these effects were prevented by L-NAME but not D-NAME. 5. Gastrointestinal transit of a non-absorbable marker (charcoal suspension) was increased by oral magnesium sulphate from a mean value of 54.1% to 72.9% (P < 0.01), and this was prevented by pretreatment with L-NAME. 6. The results demonstrate that oral magnesium sulphate produces diarrhoea in rats by increasing the accumulation of fluid in the intestinal lumen and enhancing flow from the proximal to distal intestine. The mechanism involves release of NO, probably through stimulation of the constitutive form of NO synthase. Whether or not the effects of magnesium sulphate are due to an osmotic action or an intrinsic effect of the magnesium or sulphate ions cannot be determined from these experiments.
摘要
  1. 研究了硫酸镁对大鼠腹泻、液体分泌、胃肠转运及一氧化氮(NO)合酶活性的影响。2. 口服剂量为2 g kg-1的硫酸镁可引起腹泻,NO合酶抑制剂NG-硝基-L-精氨酸甲酯(L-NAME)可使其起效时间延迟且强度呈剂量依赖性降低。NO前体L-精氨酸和NO供体化合物5-单硝酸异山梨酯(IMN)可预防这种情况。3. 给大鼠服用硫酸镁后,肠道组织中的NO合酶活性受到刺激,L-NAME可抑制此作用。诱导型NO合酶抑制剂地塞米松(1 mg kg-1,腹腔注射)对硫酸镁诱导的腹泻无影响。4. 硫酸镁刺激肠腔内液体和电解质积聚;L-NAME可预防这些作用,但D-NAME不能。5. 口服硫酸镁可使不可吸收标记物(木炭悬液)的胃肠转运从平均值54.1%增加到72.9%(P < 0.01),L-NAME预处理可预防此作用。6. 结果表明,口服硫酸镁通过增加肠腔内液体积聚和增强从近端肠到远端肠的流动而导致大鼠腹泻。其机制可能涉及通过刺激组成型NO合酶释放NO。从这些实验无法确定硫酸镁的作用是否归因于渗透作用或镁离子或硫酸根离子的内在效应。

相似文献

引用本文的文献

2
Management of chronic constipation in patients with diabetes mellitus.糖尿病患者慢性便秘的管理
Indian J Gastroenterol. 2017 Jan;36(1):11-22. doi: 10.1007/s12664-016-0724-2. Epub 2016 Dec 17.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验